 |
11 Diseases |  |
38 Trials |
|
38 Trials |  |
2690 News |  |
| 12345678910111213...3839» |
- || Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
Review, Journal: Biologics as a novel treatment option for palmoplantar pustulosis: a comprehensive review. (Pubmed Central) - Jul 19, 2024
However, the effectiveness of other biologics remains uncertain due to limited data. More research is needed to find effective treatments for PPP, and selecting the right biologic for each patient is challenging.
- ||| Tremfya (guselkumab) / J&J
Trial completion date: SPECTREM: Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (clinicaltrials.gov) - Jul 17, 2024
P3, N=300, Recruiting, Sponsor: Janssen Research & Development, LLC
More research is needed to find effective treatments for PPP, and selecting the right biologic for each patient is challenging. Trial completion date: May 2025 --> Dec 2025
- |||| Tremfya (guselkumab) / J&J
Trial completion date, Trial primary completion date: PsABIOnd: A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice (clinicaltrials.gov) - Jul 17, 2024
P=N/A, N=1314, Active, not recruiting, Sponsor: Janssen Pharmaceutica N.V., Belgium
Trial completion date: May 2025 --> Dec 2025 Trial completion date: Dec 2027 --> Aug 2027 | Trial primary completion date: Dec 2027 --> Aug 2027
- || Tremfya (guselkumab) / J&J
Trial completion date: STAR: A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease (clinicaltrials.gov) - Jul 17, 2024
P4, N=405, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: Dec 2027 --> Aug 2027 | Trial primary completion date: Dec 2027 --> Aug 2027 Trial completion date: Jun 2026 --> Feb 2026
- ||| P2 data, P3 data, Review, Journal: Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment-insights from Phase II and III trials. (Pubmed Central) - Jul 9, 2024
The clinical trials indicate that both S1P modulators and IL-23 inhibitors offer promising therapeutic benefits and maintain strong safety profiles, positioning them as potential cornerstone treatments for IBD. Despite these advancements, further exploration into long-term safety and the development of personalized treatment strategies is essential for maximizing clinical outcomes.
- | Remicade (infliximab) / J&J, Tremfya (guselkumab) / J&J
Journal: Long-term clinical course of two rare cases of synovitis-acne-pustulosis-hyperostosis-osteomyelitis syndrome involving only unilateral femur. (Pubmed Central) - Jul 8, 2024
X-rays of the femur showed cortical thickening. SAPHO syndrome can be managed with drug therapies, such as nonsteroidal anti-inflammatory drugs, methotrexate, and conventional synthetic disease-modifying antirheumatic drugs; however, there are occasional treatment-resistant cases.
- | Tremfya (guselkumab) / J&J
Journal: Successful treatment of hydrarthrosis of the knee with guselkumab in a patient with palmoplantar pustulosis. (Pubmed Central) - Jul 4, 2024
SAPHO syndrome can be managed with drug therapies, such as nonsteroidal anti-inflammatory drugs, methotrexate, and conventional synthetic disease-modifying antirheumatic drugs; however, there are occasional treatment-resistant cases. No abstract available
- | Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
Journal: A Successful Switch From Ustekinumab to an Extended Dosing Interval of Guselkumab Without Induction in a Patient With Psoriasis Vulgaris. (Pubmed Central) - Jul 4, 2024
We herein present the first case of a successful transition from UST 90 mg to an extended dosing interval of GUS without an induction phase. This approach may be a viable and cost-saving option, especially for patients with relatively low disease activity.
- | Journal: [[Translated article]]Comparing the Use of Topical Therapy Along with Anti-IL-17 and Anti-IL-23 to Treat Moderate-to-Severe Psoriasis in the Routine Clinical Practice. (Pubmed Central) - Jul 2, 2024
In our cohort, we saw a significant decrease in the frequency of use of TT at 6 months after starting BT in the routine clinical practice. This reduction occurred earlier in patients who improved their objective clinical response and quality of life.
- | Journal: Comparing the use of topical therapy along with anti-IL17 and anti-IL23 to treat moderate-to-severe psoriasis in the routine clinical practice. (Pubmed Central) - Jul 2, 2024
In our cohort, we saw a significant decrease in the frequency of use of TT at 6 months after starting BT in the routine clinical practice. This reduction occurred earlier in patients who improved their objective clinical response and quality of life.
- | Tremfya (guselkumab) / J&J
Journal: Effectiveness of guselkumab in patients with facial and/or genital psoriasis: Interim analysis results at Week 12 from the GULLIVER study. (Pubmed Central) - Jun 26, 2024
This reduction occurred earlier in patients who improved their objective clinical response and quality of life. Guselkumab, showing to be effective and safe in treating FP and GP, may be a valid therapeutic option for patients with psoriasis localized in these difficult-to-treat areas.
- || Clinical, Retrospective data, Review: Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis. (Pubmed Central) - Jun 20, 2024
This meta-analysis showed that the investigated IL-17 and IL-23 inhibitors had high drug survival rates, with highest rates for guselkumab and risankizumab drug survival. We showed that effect modifiers such as biologic naivety, and the source of data used (registry/electronic health record data vs pharmacy/claims databases) is relevant when interpreting drug survival studies.
- | Tremfya (guselkumab) / J&J
Journal: Prior exposure to fumaric acid esters does not impact on subsequent treatment response to guselkumab. (Pubmed Central) - Jun 20, 2024
We showed that effect modifiers such as biologic naivety, and the source of data used (registry/electronic health record data vs pharmacy/claims databases) is relevant when interpreting drug survival studies. No abstract available
- ||| Tremfya (guselkumab) / J&J
P3 data, Journal: Guselkumab demonstrates long-term efficacy and maintenance of treatment response post-withdrawal in systemic-treatment na (Pubmed Central) - Jun 20, 2024
No abstract available In these exploratory analyses, GUS, as a first-line systemic treatment or second-line systemic treatment in FAE nonresponders, was associated with long-term clinical efficacy up to week 100, including a withdrawal period.
- | Tremfya (guselkumab) / J&J
Journal: Long-term response to treatment with (Pubmed Central) - Jun 20, 2024
In these exploratory analyses, GUS, as a first-line systemic treatment or second-line systemic treatment in FAE nonresponders, was associated with long-term clinical efficacy up to week 100, including a withdrawal period. No abstract available
- | Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim, Tremfya (guselkumab) / J&J
Journal: Matching-adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline Psoriasis Area and Severity Index from week 4 to 40. (Pubmed Central) - Jun 17, 2024
No abstract available No abstract available
- | Tremfya (guselkumab) / J&J
Journal: Multirefractory bullous pemphigoid, psoriasis and psoriatic arthritis successfully treated with guselkumab. (Pubmed Central) - Jun 15, 2024
No abstract available No abstract available
- | Tremfya (guselkumab) / J&J
Journal: The role of guselkumab in psoriatic artrithis and disease progression in patients with confirmed diagnosis of enthesitis. (Pubmed Central) - Jun 3, 2024
No abstract available No abstract available
- Tremfya (guselkumab) / J&J
IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES THROUGH 6 MONTHS OF GUSELKUMAB TREATMENT IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: REAL-WORLD DATA FROM THE COREVITAS PSORIATIC ARTHRITIS/SPONDYLOARTHRITIS REGISTRY () - May 29, 2024 - Abstract #EULAR2024EULAR_4571;
In this real-world population of patients with treatment-resistant active PsA and persistent on-label GUS use, consistent with prior results for physician-reported endpoints of joint and skin disease, patients reported meaningful improvements in pain, physical function, and fatigue. These represent difficult-to-treat domains that are important contributors to the health-related quality of life of patients.
- Tremfya (guselkumab) / J&J
GUSELKUMAB INDUCTION RESTORES INTESTINAL IMMUNE HOMEOSTASIS AND PROMOTES EPITHELIAL REPAIR IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_4361;
P2/3
GUS induction restored intestinal immune homeostasis in patients with UC who achieved key endpoints at WK12, demonstrated by resolution of inflammation associated with the IL-23 pathway and inflammatory myeloid, epithelial and fibroblast transcriptional states. GUS also promoted epithelial repair as evidenced by increases in epithelial cell population, consistent with endoscopic and histologic outcomes at WK12.
- Simponi (golimumab) / Merck (MSD), Mitsubishi Tanabe, J&J, Tremfya (guselkumab) / J&J
GUSELKUMAB AND GOLIMUMAB COMBINATION INDUCTION THERAPY IN ULCERATIVE COLITIS RESULTS IN EARLY LOCAL TISSUE HEALING THAT IS SUSTAINED THROUGH GUSELKUMAB MAINTENANCE THERAPY () - May 29, 2024 - Abstract #EULAR2024EULAR_4360;
P2
Correlative analysis supports the role of GUS as the primary driver of tissue healing, with GOL further contributing to innate inflammatory activity, which demonstrate differential and complementary mechanisms of action of TNF? and IL-23p19 subunit blockade.
- Tremfya (guselkumab) / J&J
EARLY SYMPTOMATIC IMPROVEMENT WITH GUSELKUMAB INDUCTION TREATMENT IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY () - May 29, 2024 - Abstract #EULAR2024EULAR_4354;
P2/3
GUS 200mg IV induction was effective in improving symptoms as early as 1 week after the first dose in patients with moderately to severely active UC. Symptomatic improvements increased through Week 12.
- Tremfya (guselkumab) / J&J
MUSCULOSKELETAL ULTRASOUND ABNORMALITIES IN PATIENTS WITH PSORIASIS AT HIGH RISK OF PROGRESSION TO PSORIATIC ARTHRITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_4215;
P4
Objectives: The ongoing Preventing Arthritis in a Multicenter Psoriasis At Risk cohort (PAMPA) study (NCT05004727) aims to evaluate the efficacy of the fully human interleukin (IL)-23p19-subunit inhibitor guselkumab in preventing PsA and reducing musculoskeletal ultrasound (US) abnormalities in a population of patients with psoriasis at increased risk of PsA progression... In a biologic-na
- Tremfya (guselkumab) / J&J
LONGITUDINAL EVALUATION OF NEUTROPHIL-TO-LYMPHOCYTE RATIO IN GUSELKUMAB-TREATED PATIENTS WITH PSORIATIC DISEASE AND LEVELS OF SYSTEMIC INFLAMMATION ASSOCIATED WITH ELEVATED CARDIOVASCULAR RISK: POST HOC ANALYSIS OF 4 PHASE 3, RANDOMIZED, CONTROLLED STUDIES () - May 29, 2024 - Abstract #EULAR2024EULAR_4212;
Together with stable BMI/SBP/DBP for up to 2Y, findings are consistent with the GUS safety profile established through 5Y. [4]
- Rinvoq (upadacitinib) / AbbVie, Humira (adalimumab) / AbbVie
IMPACT OF URICEMIA ON PSORIATIC ARTHRITIS, AND ON SAFETY AND CLINICAL RESPONSE TO UPADACITINIB AND ADALIMUMAB: POST-HOC ANALYSIS OF PHASE III STUDIES () - May 29, 2024 - Abstract #EULAR2024EULAR_4204;
The observed differential clinical profile and comorbidities, which confirm previous studies 3 , underscore the value of assessing serum urate levels in PsA pts. Pts with HU were more prone to develop hypertension or diabetes mellitus.
- Tremfya (guselkumab) / J&J
GUSELKUMAB PROVIDES CLINICALLY MEANINGFUL IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS WHO ARE INADEQUATE RESPONDERS TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS THROUGH ONE YEAR OF A PHASE 3b, RANDOMIZED, CONTROLLED STUDY (COSMOS) () - May 29, 2024 - Abstract #EULAR2024EULAR_4198;
Pts with HU were more prone to develop hypertension or diabetes mellitus. In pts with PsA with TNFi-IR, GUS was associated with rapid effect for achievement of MCIIs and sustained achievement of more rigorous response criteria across PROs, including patient-reported skin and joint symptoms, pain, fatigue, functional status, and skin-specific and physical function-related QoL, with increasing response rates from W24 to W48.
- Tremfya (guselkumab) / J&J
EFFICACY OF GUSELKUMAB IN EARLY-ONSET AND LATE-ONSET PSORIATIC ARTHRITIS: POST HOC POOLED ANALYSES OF TWO PHASE 3 RANDOMIZED CONTROLLED TRIALS IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS () - May 29, 2024 - Abstract #EULAR2024EULAR_4192;
In pts with PsA with TNFi-IR, GUS was associated with rapid effect for achievement of MCIIs and sustained achievement of more rigorous response criteria across PROs, including patient-reported skin and joint symptoms, pain, fatigue, functional status, and skin-specific and physical function-related QoL, with increasing response rates from W24 to W48. Results of post hoc analyses, conducted in a large cohort of mainly bio-na
- Tremfya (guselkumab) / J&J
EFFICACY OF GUSELKUMAB IN BIONAIVE PSORIATIC ARTHRITIS PATIENTS WITH SEVERE DISEASE ACTIVITY: POST-HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY () - May 29, 2024 - Abstract #EULAR2024EULAR_4191;
In bionaive PsA pts with severe DA based on a range of joint-focused and multi-domain outcomes, GUS led to rapid (W2 for joint and W8 for overall disease activity) clinically meaningful improvements in disease activity; these improvements were further enhanced by W24 and sustained through 2 years. Overall, findings support the use of GUS for the treatment of PsA pts presenting with severe DA.
- Tremfya (guselkumab) / J&J
EFFECTS OF GUSELKUMAB ON cDAPSA DISEASE ACTIVITY STATE AND ITS ASSOCIATION WITH LONG-TERM RADIOGRAPHIC PROGRESSION IN A COHORT OF PATIENTS WITH MODERATELY-HIGHLY ACTIVE PSORIATIC ARTHRITIS: POST HOC ANALYSES OF PHASE 3 RANDOMIZED CONTROLLED STUDIES () - May 29, 2024 - Abstract #EULAR2024EULAR_4188;
Among PsA pts with ModDA/HDA, GUS was associated with significantly greater rates of cDAPSA LDA/REM achievement vs. PBO at W8 (after 2 doses). Response rates increased over time, with nearly 40% and >50% of GUS-randomized pts achieving cDAPSA LDA/REM at Weeks 24 and 52, respectively.
- Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim, Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
EFFECTIVENESS IN THE AXIAL DOMAIN OF IL-12/23 AND IL23 INHIBITORS IN AXIAL AND/OR MIXED PSORIATIC ARTHRITIS: MULTICENTER OBSERVATIONAL STUDY (APxis-IL12-23) () - May 29, 2024 - Abstract #EULAR2024EULAR_4187;
Objectives: To evaluate the effectiveness of ustekinumab (UST), guselkumab (GUS), and risankizumab(RSK) in patients with axial and/or mixed PsA, focusing on the axial domain, in real clinical practice. In our experience in clinical practice, GUS and RSK demonstrate effectiveness at 1 year in the axial domain in patients with PsA.
- Tremfya (guselkumab) / J&J
EARLY FATIGUE IMPROVEMENT WITH GUSELKUMAB ASSOCIATES WITH LONGER TERM DISEASE CONTROL IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS REPORTING SUBSTANTIAL FATIGUE: POST HOC ANALYSES OF A SUB-POPULATION OF A PHASE 3, RANDOMIZED, CONTROLLED TRIAL OF GUSELKUMAB IN BIOLOGIC-NA () - May 29, 2024 - Abstract #EULAR2024EULAR_4185;
In our experience in clinical practice, GUS and RSK demonstrate effectiveness at 1 year in the axial domain in patients with PsA. In this sub-population of biona
- Tremfya (guselkumab) / J&J
COMPARISON OF ON-LABEL TREATMENT PERSISTENCE IN REAL-WORLD PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING GUSELKUMAB VERSUS SUBCUTANEOUS TNF INHIBITORS () - May 29, 2024 - Abstract #EULAR2024EULAR_4174;
Adults with PsA newly initiated on guselkumab or the first observed SC TNFi (i.e., adalimumab, certolizumab pegol, etanercept, or SC golimumab) between 7/14/2020 and 3/31/2022 were selected from the IQVIA TM Health Plan Claims Data. This real-world study assessing treatment persistence in PsA using administrative claims data demonstrated that guselkumab was associated with significantly longer on-label persistence through 12 months versus SC TNFi.
- Tremfya (guselkumab) / J&J
BASELINE CHARACTERISTICS OF REAL-WORLD PSORIATIC ARTHRITIS PATIENTS TREATED WITH GUSELKUMAB OR IL-17 INHIBITORS: RESULTS FROM THE ONGOING MULTINATIONAL PSABIOND STUDY () - May 29, 2024 - Abstract #EULAR2024EULAR_4162;
P
On average, pts across treatments were characterized by moderate-to-severe joint disease activity, multi-domain disease, and impaired activity and work productivity. Compared with pts treated with IL-17i, GUS was more often given in pts with more severe skin disease and obesity.
- | Journal: Interleukin-23 inhibitors decrease Fibrosis-4 index in psoriasis patients with elevated Fibrosis-4 index but not inteleukin-17 inhibitors. (Pubmed Central) - May 28, 2024
Furthermore, IL-23 inhibitors (but not IL-17 inhibitors) decreased the FIB-4 index score at 6?months in psoriasis patients with elevated FIB-4 index scores at baseline. Further studies are needed to clarify whether IL-23 inhibitors improve liver fibrosis physiologically and functionally.
- || Review, Journal: Biologics for Psoriasis. (Pubmed Central) - May 26, 2024
IL-23 inhibitors had lowest rates of short-term and long-term adverse events and most favorable long-term risk-benefit profile compared to IL-17, IL-12/23, and TNF-? inhibitors.
- | Retrospective data, Journal, HEOR: Treatment Discontinuation in Patients with Psoriasis Treated with Biologics: A Retrospective Analysis of German Health Claims Data. (Pubmed Central) - May 24, 2024
inhibitors. Further research should explore reasons leading to treatment discontinuation in order to support treatment choices for patients with moderate-to-severe psoriasis.
- | Tremfya (guselkumab) / J&J
Journal, Real-world evidence, Real-world: Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumab. (Pubmed Central) - May 22, 2024
Modest sample size and the retrospective nature of the study. Guselkumab not only demonstrates high effectiveness in treating psoriasis but also exhibits a favorable safety profile in patients with neoplasms.
- Tremfya (guselkumab) / J&J
EFFICACY AND SAFETY OF GUSELKUMAB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS OF THE GALAXI 2 & 3 PHASE 3 STUDIES (146C - Walter E. Washington Convention Center) - May 18, 2024 - Abstract #DDW2024DDW_8700;
- | Journal: Dose escalation of biologic treatment in patients with moderate-to-severe psoriasis in Japan. (Pubmed Central) - May 17, 2024
In multivariable-adjusted analyses, odds of dose escalation were significantly lower for all products relative to UST. In sensitivities, escalation was observed for all products except RIS.
- | Journal: Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis. (Pubmed Central) - May 15, 2024
In sensitivities, escalation was observed for all products except RIS. The results of this SLR informed the task force responsible for the 2023 update of the European Alliance of Associations for Rheumatology recommendations for pharmacological management of PsA.
- | Journal: Vaccination Recommendations for Adults Receiving Biologics and Oral Therapies for Psoriasis and Psoriatic Arthritis: Delphi Consensus from the Medical Board of the National Psoriasis Foundation. (Pubmed Central) - May 15, 2024
The results of this SLR informed the task force responsible for the 2023 update of the European Alliance of Associations for Rheumatology recommendations for pharmacological management of PsA. Interruption of antipsoriatic oral and biologic therapies is generally not necessary for
- || Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Tremfya (guselkumab) / J&J, Cosentyx (secukinumab) / Novartis
Clinical, Retrospective data, Journal: Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States. (Pubmed Central) - May 15, 2024
At 6 months after index biologic discontinuation, the guselkumab cohort was 31% and 40% more likely to achieve remission than secukinumab (rate ratio [RR] = 1.31; p < 0.001) and ixekizumab cohorts (RR = 1.40; p < 0.001). Guselkumab was associated with greater persistence and likelihood of remission than IL-17 inhibitors, indicating greater disease control and modification potential.
- || Tremfya (guselkumab) / J&J
P4 data, Journal: Safety and effectiveness of guselkumab in Japanese patients with psoriasis: 20-week interim analysis of a postmarketing surveillance study. (Pubmed Central) - May 15, 2024
Our findings demonstrate that guselkumab is well tolerated and effective in Japanese patients with psoriasis through 20?weeks of treatment in real-world clinical practice, showing significant effectiveness observed as early as 4?weeks. The study was officially registered with the University Hospital Medical Information Network Clinical Trials Registry with the identifier UMIN000032969.
- || Review, Journal: Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence. (Pubmed Central) - May 12, 2024
Low doses, intermittent treatment may increase ADA formation. An appropriate biologic should be selected based on the ADA formation rate and course of treatment.
- | Tremfya (guselkumab) / J&J
Journal: Successful treatment with guselkumab of anti-p200 pemphigoid associated with plaque psoriasis. (Pubmed Central) - May 11, 2024
An appropriate biologic should be selected based on the ADA formation rate and course of treatment. No abstract available
- | Tremfya (guselkumab) / J&J
Journal: Long-Term Efficacy and Safety of Guselkumab in Psoriasis Patients Who Failed Anti-IL17: A Two-Year Real-Life Study. (Pubmed Central) - May 11, 2024
Primary and secondary inefficacy were reported by 1 (1.6%) and 5 (8.2%) patients. As regards safety, no severe AEs were collected.
- || Stelara (ustekinumab) / J&J, Tremfya (guselkumab) / J&J
Clinical, Journal: Real-Life Effectiveness and Safety of Guselkumab in Patients with Psoriasis Who Have an Inadequate Response to Ustekinumab: A 3-Year Multicenter Study. (Pubmed Central) - May 11, 2024
In contrast, the efficacy of guselkumab does not seem to be affected by the BMI, involvement of fingernails, or location in the genital or scalp area. To sum up, our long-term real-life multicenter retrospective study confirmed the efficacy and safety of guselkumab following ustekinumab discontinuation up to 156 weeks of treatment.
- | Tremfya (guselkumab) / J&J
Journal: Erfolgreiche Behandlung eines Anti?P200?Pemphigoids in Verbindung mit Plaque?Psoriasis mit Guselkumab: Successful treatment with guselkumab of anti?p200 pemphigoid associated with plaque psoriasis. (Pubmed Central) - May 11, 2024
To sum up, our long-term real-life multicenter retrospective study confirmed the efficacy and safety of guselkumab following ustekinumab discontinuation up to 156 weeks of treatment. No abstract available
- | Tremfya (guselkumab) / J&J
Biomarker, Journal: Exposure-response relationship of guselkumab and the potential of serum proteomics in identifying predictive biomarker candidates in psoriasis. (Pubmed Central) - May 8, 2024
No biomarker candidates were identified through serum proteomics. We propose protein screening should be repeated in larger cohorts to continue the quest for predictive biomarkers.
- || Retrospective data, Review, Journal: Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis. (Pubmed Central) - May 5, 2024
We propose protein screening should be repeated in larger cohorts to continue the quest for predictive biomarkers. Among all available biologics and small-molecule inhibitors, secukinumab 300 mg and guselkumab 100 mg had the most favorable efficacy in treating PP and PPP, respectively.